AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications validating its POSH (Pooled Optical Screening in Human cells) platform. The study ...

Baylor College of Medicine will be a site for a new multi-institution project aimed at investigating preclinical drug safety assessments. The ...

Discovering effective drug combinations may now be easier thanks to a screening platform made public today by St. Jude ...

Variational AI, a Vancouver-based generative artificial intelligence (AI) drug discovery startup, is solving this problem by shifting from screening to generating. At the heart of its technology is ...

In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...

In drug discovery, scientists identify promising compounds and work to develop them into effective therapeutics. However, they often struggle to navigate expansive compound libraries and prioritize ...

Thousands of proteins are known to cause disease, but while the biological activity of these proteins is understood, the way to hit and modulate them with a drug is not. Nature still has ways to bind ...

Project Overdose is introducing an artificial intelligence tool that can alert communities about what potentially deadly ...

After reportedly flirting with going public for years, the artificial intelligence-powered drug developer Insilico Medicine ...

State-of-the-art AI programs can support the development of drugs by predicting how proteins interact with small molecules. However, a new study by researchers at the University of Basel published in ...

The local pharmacy used to be the default place to fill prescriptions, but like just about everything else, technology is ...